Molecular genotyping is performed in anti-malarial trials to determine whether recurrent
parasitaemia after therapy represents a recrudescence (treatment failure) or new infection. The use of capillary
instead of agarose gel electrophoresis for genotyping offers technical advantages, but it is unclear whether
capillary electrophoresis will result in improved classification of anti-malarial treatment outcomes.